These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Chimeric antigen receptors: "CARs" in the fast lane for rheumatology. Johnson NM; Koumpouras F Curr Opin Rheumatol; 2024 May; 36(3):176-183. PubMed ID: 38517338 [TBL] [Abstract][Full Text] [Related]
24. Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders. Kahmini FR; Shahgaldi S Mol Biol Rep; 2022 May; 49(5):4069-4078. PubMed ID: 35534581 [TBL] [Abstract][Full Text] [Related]
25. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Haghikia A; Schett G; Mougiakakos D Lancet Neurol; 2024 Jun; 23(6):615-624. PubMed ID: 38760099 [TBL] [Abstract][Full Text] [Related]
27. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Qin C; Dong MH; Zhou LQ; Wang W; Cai SB; You YF; Shang K; Xiao J; Wang D; Li CR; Zhang M; Bu BT; Tian DS; Wang W Proc Natl Acad Sci U S A; 2024 Feb; 121(6):e2315990121. PubMed ID: 38289960 [TBL] [Abstract][Full Text] [Related]
28. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Shah K; Leandro M; Cragg M; Kollert F; Schuler F; Klein C; Reddy V Clin Exp Immunol; 2024 Jun; 217(1):15-30. PubMed ID: 38642912 [TBL] [Abstract][Full Text] [Related]
29. The Future of CAR T Therapeutics to Treat Autoimmune Disorders. Pecher AC; Hensen L; Lengerke C; Henes J Mol Diagn Ther; 2024 Sep; 28(5):593-600. PubMed ID: 39078456 [TBL] [Abstract][Full Text] [Related]
30. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Motte J; Sgodzai M; Schneider-Gold C; Steckel N; Mika T; Hegelmaier T; Borie D; Haghikia A; Mougiakakos D; Schroers R; Gold R Neuron; 2024 Jun; 112(11):1757-1763.e2. PubMed ID: 38697115 [TBL] [Abstract][Full Text] [Related]
31. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production. Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226 [TBL] [Abstract][Full Text] [Related]
32. Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment. Adabi N; Pordel S; Rezaee MA; Shobeiri FS; Shobeiri SS J Gene Med; 2023 May; 25(5):e3484. PubMed ID: 36781390 [TBL] [Abstract][Full Text] [Related]
33. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639 [TBL] [Abstract][Full Text] [Related]
34. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215 [TBL] [Abstract][Full Text] [Related]
35. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. Bachmann M Immunol Lett; 2019 Jul; 211():13-22. PubMed ID: 31091431 [TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Abramson JS; Lunning M; Palomba ML Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671 [TBL] [Abstract][Full Text] [Related]
38. Engineered T cells and their therapeutic applications in autoimmune diseases. Bao L; Bo XC; Cao HW; Qian C; Wang Z; Li B Zool Res; 2022 Mar; 43(2):150-165. PubMed ID: 35008131 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases. Su M; Zhao C; Luo S Autoimmun Rev; 2022 Jan; 21(1):102931. PubMed ID: 34481941 [TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]